Syncom Formulations Reports Strong Q3 Results, Highlighting Consistent Sales Growth

Syncom Formulations (India), a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a notable performance, with the company's score reflecting an adjustment in evaluation from the previous period. The quarter saw net sales reaching Rs 127.53 crore, marking a significant growth compared to the average net sales of the last four quarters. This upward trend in sales has been consistent over the past five quarters, suggesting a robust near-term sales trajectory. Operating profit also reached a peak of Rs 14.73 crore, continuing the positive trend observed in previous quarters. Similarly, profit before tax (PBT) was reported at Rs 13.22 crore, showcasing a substantial increase over the average PBT from the prior four quarters. Profit after tax (PAT) followed suit, hitting Rs 13.00 crore, further emphasizing the company's strong financial health. Earnings per share (EPS) also reached its highest level in the last five quarters, indicating enhanced profitability for shareholders. Overall, Syncom Formulations (India) has demonstrated a solid financial performance in this reporting period. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.